Patriot Act and PSE
This article was originally published in The Tan Sheet
Executive Summary
Provisions requiring behind-the-counter placement of products containing pseudoephedrine have been added to the final version of the conference report for the Patriot Act reauthorization package. The report was filed Dec. 8 and will be considered by the House and Senate during the week of Dec. 12, House Judiciary Committee Chairman James Sensenbrenner (R-Wis.), announces. The provision for BTC sale was first added to the draft version of the conference report in November (1"The Tan Sheet" Nov. 28, 2005, p. 3). Also added at that time were essentially all elements of the Talent/Feinstein Combat Meth Act (S 103), except for the provision requiring Schedule V status for pseudoephedrine. The conference report's final version contains a new pseudoephedrine sales limit of 9 g/30 days...
You may also be interested in...
Anti-Meth Draft Places PSE Behind Counter, Lacks Schedule V Language
Current draft report language in the Patriot Act places all pseudoephedrine products behind the counter but does not contain a Schedule V provision, according to the Consumer Healthcare Products Association
Exec Chat: How Edwards Lifesciences Deploys AI, Remote Monitoring To Help Doctors Make Life-Critical Decisions
Edwards Lifesciences’ head of critical care expects that “smart recovery” AI-driven products will grow the fastest in its critical care unit, which is expected to reach $800m in total revenues for 2021.
Cara Placing Korsuva Hopes On Oral Formulation, Broad Pruritis Label
I.V. Korsuva now has an August FDA action date, which partner Vifor would commercialize in the ESRD dialysis setting while Cara works toward a broad anti-pruritus label for its oral tablet formulation.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: